Year in review...
Retinal
Aug. 12, 2013 - Amarantus Announces Positive Orphan Data for MANF in Retinitis Pigmentosa
Dec. 3, 2013 - Amarantus Obtains Exclusive Option to License University of Miami Bascom Palmer Eye Institute's Intellectual Property for the Treatment of Retinal Diseases Using MANF and CDNF
March 3, 2014 - Amarantus Outlines MANF Research Collaboration Strategy
July 2, 2014 - Amarantus Announces Positive Interim Toxicology Data for MANF in Retinitis Pigmentosa
Aug. 11, 2014 - Amarantus Enters Into Research Collaboration With the Buck Institute for Research on Aging for MANF
Aug. 11, 2014 - Company Acquires Exclusive Option to License Undisclosed MANF IP from Buck Institute for Research on Aging
Aug. 15, 2014 - Amarantus to License Intellectual Property From Bascom Palmer Eye Institute for Use of MANF in Retinal Disorders
Aug. 26, 2014 - Amarantus enters into a master services agreement with ICON Clinical Research Limited pursuant to which the Company retained ICON to provide the Company with certain central laboratory services in connection with certain research studies
Sept. 9, 2014 - Amarantus Announces Positive MANF Ocular Toxicology Data
Oct. 1 2014 - Amarantus enters into a sponsored research agreement with the University of Miami on the use of MANF in retinal disorders
Oct. 7, 2014 - Amarantus Investigator Presents Positive MANF Animal Data in Central Retinal Vein Occlusion and Glaucoma at the Targeting Ocular Disorders Conference
Oct. 16, 2014- Amarantus Applies to FDA for MANF Orphan Drug Designation in Retinitis Pigmentosa
Alzheimer Therapeutic
May 1, 2014 - Amarantus Announces Positive Independent Peer-Reviewed Preclinical Data for MANF in Alzheimer's and Diabetes
July 1, 2014 - Amarantus Independently Confirms Published Chinese Positive MANF Tau Phosphorylation Data for Alzheimer's Disease
Aug. 1, 2014 - Amarantus BioSciences, Inc. Acquires Exclusive Option To License Alzheimer's Therapeutic IP Of Dr. Thomas Arendt From University of Leipzig
Alzheimer Diagnostic
Oct. 14, 2013 - Amarantus Announces Positive Analytical Performance Data for LymPro Test(R) for Alzheimer's Disease
Jan. 29, 2014 - Amarantus Establishes LymPro Research Collaboration With Boston University School of Medicine
May 5, 2014 - Amarantus Acquires Additional Rights to LymPro Test From Memory Dx
July 15, 2014 -Amarantus Announces Positive Clinical Performance and 7-Year Longitudinal Data Poster Presentations for LymPro Test at AAIC 2014
Aug. 1, 2014 - Amarantus Announces Positive Top-Line Interim Clinical Data for Alzheimer's Blood Diagnostic LymPro Test
Sept. 2, 2014 - Amarantus Initiates CLIA Development of Alzheimer's Blood Diagnostic LymPro Test(R) at ICON Central Laboratories
Sept. 12, 2014 - Amarantus Completes Enrollment of 72 Patient LP-002 Clinical Study for Alzheimer's Blood Diagnostic LymPro Test
Oct. 9, 2014 - Amarantus Announces Positive LP-002 Data for Alzheimer's Blood Diagnostic LymPro Test
Diagnostic
Oct. 27, 2014 - We are actively evaluating additional complementary late-stage neurology-focused diagnostic assets that would bolster our diagnostic division and make for a successful ‘spin-out’ while concurrently returning value to our shareholders. We believe we will be able to execute on this strategy in the near-term.
Wolfram
Dec. 18, 2013 - Amarantus Licenses MANF-Related Wolfram's and Diabetes Therapeutic and Diagnostic Intellectual Property From University of Massachusetts Medical School
June 20, 2014 - Amarantus entered into research collaboration with the Washington University School of Medicine
Eltoprazine
Jan. 14, 2014 - Amarantus In-Licenses Levadopa-Induced Dyskinesia Phase 2b-Ready Eltoprazine From PGI Drug Discovery
February 4, 2014 - Amarantus Announces Positive Phase 2a Data for Eltoprazine in Adult ADHD
Sept. 17, 2014 - Amarantus Provides Program Update on Phase 2b Eltoprazine for Parkinson's Disease and Adult ADHD
Sept. 29, 2014 - Amarantus Requests Pre-IND Feedback From FDA for Eltoprazine Phase IIb Parkinson's Disease Levodopa-Induced Dyskinesia Clinical Trial
What's Next - We are looking forward to receiving pre-IND feedback from the FDA later in the fourth quarter and being able to open a new IND in the Neurology Division of FDA shortly thereafter. The Phase 2b trial is on schedule to start in early 2015.
PhenoGuard
Nov. 12th, 2013 - We expect to be in a position to start collaborating on this project in early 2014 having expanded our PhenoGuard cell line library to 88 cell lines from four distinct brain regions associated with Parkinson’s, Alzheimer’s, Clinical Depression and Huntington’s disease.
April 28, 2014 - Amarantus CSO to Present on PhenoGuard Data at Astrocytes in Health and Neurodegenerative Disease in London - To date, we have screened 37 of our library of 88 astrocyte cell lines. All 37 ACMs screened to date secrete neuroprotective molecules, and several meet the criteria for further analysis as potential drug candidates for PD.
Otology
March 6, 2014 - Amarantus Acquires Exclusive Option to License Intellectual Property for Use of MANF and CDNF to Treat Antibiotic-Induced Ototoxicity
People
Sept. 3, 2013 - Amarantus Appoints Dr. Colin Bier to Advisory Board for LymPro Commercialization
Sept. 13, 2013 - Amarantus Appoints F. Randall Grimes, MBA as Director of Sponsored Research
Nov. 6, 2013 - Amarantus Appoints David A. Lowe, PhD to Board of Directors
Feb. 24, 2014 - Amarantus Strengthens Management Team With Key Additions in Business Development and Regulatory Affairs (Kerry Segal as Head of Business Development and Tiffini Clark as Head of Regulatory Affairs)
March 31, 2014 - Amarantus Appoints Dr. Louis Kirby to Board of Advisors
April 1, 2014 - Amarantus Appoints Robert Farrell, J.D. as Chief Financial Officer
April 8, 2014 - Amarantus Appoints Dr. Charlotte Keywood Chief Medical Officer of Its Therapeutics Division
July 28, 2014 - Amarantus Appoints Donald D. Huffman to Board of Directors
Aug. 29, 2014 - Amarantus Appoints Iain Ross to Board of Directors
Place
Oct. 30, 2013 - Amarantus Relocates Headquarters to Janssen Labs @QB3 Incubator in San Francisco
May 6, 2014 - Amarantus Establishes Office in Geneva, Switzerland
Aug. 2014 - Amarantus relocates its priciple offices to larger space at 655 Montgomery Street IN San Francisco, California (5,700 sq.ft.) while continuing to lease office and laboratory space at Janssen Labs
Funding
Feb. 18, 2014 - Amarantus Bioscience Holdings Announces $3M Solicitation of Previously Issued Warrants
March 10, 2014 - Amarantus Closes Warrant Solicitation; Enters Into $20 Million Purchase Agreement With Lincoln Park Capital Fund, LLC
Retinal
Aug. 12, 2013 - Amarantus Announces Positive Orphan Data for MANF in Retinitis Pigmentosa
Dec. 3, 2013 - Amarantus Obtains Exclusive Option to License University of Miami Bascom Palmer Eye Institute's Intellectual Property for the Treatment of Retinal Diseases Using MANF and CDNF
March 3, 2014 - Amarantus Outlines MANF Research Collaboration Strategy
July 2, 2014 - Amarantus Announces Positive Interim Toxicology Data for MANF in Retinitis Pigmentosa
Aug. 11, 2014 - Amarantus Enters Into Research Collaboration With the Buck Institute for Research on Aging for MANF
Aug. 11, 2014 - Company Acquires Exclusive Option to License Undisclosed MANF IP from Buck Institute for Research on Aging
Aug. 15, 2014 - Amarantus to License Intellectual Property From Bascom Palmer Eye Institute for Use of MANF in Retinal Disorders
Aug. 26, 2014 - Amarantus enters into a master services agreement with ICON Clinical Research Limited pursuant to which the Company retained ICON to provide the Company with certain central laboratory services in connection with certain research studies
Sept. 9, 2014 - Amarantus Announces Positive MANF Ocular Toxicology Data
Oct. 1 2014 - Amarantus enters into a sponsored research agreement with the University of Miami on the use of MANF in retinal disorders
Oct. 7, 2014 - Amarantus Investigator Presents Positive MANF Animal Data in Central Retinal Vein Occlusion and Glaucoma at the Targeting Ocular Disorders Conference
Oct. 16, 2014- Amarantus Applies to FDA for MANF Orphan Drug Designation in Retinitis Pigmentosa
Alzheimer Therapeutic
May 1, 2014 - Amarantus Announces Positive Independent Peer-Reviewed Preclinical Data for MANF in Alzheimer's and Diabetes
July 1, 2014 - Amarantus Independently Confirms Published Chinese Positive MANF Tau Phosphorylation Data for Alzheimer's Disease
Aug. 1, 2014 - Amarantus BioSciences, Inc. Acquires Exclusive Option To License Alzheimer's Therapeutic IP Of Dr. Thomas Arendt From University of Leipzig
Alzheimer Diagnostic
Oct. 14, 2013 - Amarantus Announces Positive Analytical Performance Data for LymPro Test(R) for Alzheimer's Disease
Jan. 29, 2014 - Amarantus Establishes LymPro Research Collaboration With Boston University School of Medicine
May 5, 2014 - Amarantus Acquires Additional Rights to LymPro Test From Memory Dx
July 15, 2014 -Amarantus Announces Positive Clinical Performance and 7-Year Longitudinal Data Poster Presentations for LymPro Test at AAIC 2014
Aug. 1, 2014 - Amarantus Announces Positive Top-Line Interim Clinical Data for Alzheimer's Blood Diagnostic LymPro Test
Sept. 2, 2014 - Amarantus Initiates CLIA Development of Alzheimer's Blood Diagnostic LymPro Test(R) at ICON Central Laboratories
Sept. 12, 2014 - Amarantus Completes Enrollment of 72 Patient LP-002 Clinical Study for Alzheimer's Blood Diagnostic LymPro Test
Oct. 9, 2014 - Amarantus Announces Positive LP-002 Data for Alzheimer's Blood Diagnostic LymPro Test
Diagnostic
Oct. 27, 2014 - We are actively evaluating additional complementary late-stage neurology-focused diagnostic assets that would bolster our diagnostic division and make for a successful ‘spin-out’ while concurrently returning value to our shareholders. We believe we will be able to execute on this strategy in the near-term.
Wolfram
Dec. 18, 2013 - Amarantus Licenses MANF-Related Wolfram's and Diabetes Therapeutic and Diagnostic Intellectual Property From University of Massachusetts Medical School
June 20, 2014 - Amarantus entered into research collaboration with the Washington University School of Medicine
Eltoprazine
Jan. 14, 2014 - Amarantus In-Licenses Levadopa-Induced Dyskinesia Phase 2b-Ready Eltoprazine From PGI Drug Discovery
February 4, 2014 - Amarantus Announces Positive Phase 2a Data for Eltoprazine in Adult ADHD
Sept. 17, 2014 - Amarantus Provides Program Update on Phase 2b Eltoprazine for Parkinson's Disease and Adult ADHD
Sept. 29, 2014 - Amarantus Requests Pre-IND Feedback From FDA for Eltoprazine Phase IIb Parkinson's Disease Levodopa-Induced Dyskinesia Clinical Trial
What's Next - We are looking forward to receiving pre-IND feedback from the FDA later in the fourth quarter and being able to open a new IND in the Neurology Division of FDA shortly thereafter. The Phase 2b trial is on schedule to start in early 2015.
PhenoGuard
Nov. 12th, 2013 - We expect to be in a position to start collaborating on this project in early 2014 having expanded our PhenoGuard cell line library to 88 cell lines from four distinct brain regions associated with Parkinson’s, Alzheimer’s, Clinical Depression and Huntington’s disease.
April 28, 2014 - Amarantus CSO to Present on PhenoGuard Data at Astrocytes in Health and Neurodegenerative Disease in London - To date, we have screened 37 of our library of 88 astrocyte cell lines. All 37 ACMs screened to date secrete neuroprotective molecules, and several meet the criteria for further analysis as potential drug candidates for PD.
Otology
March 6, 2014 - Amarantus Acquires Exclusive Option to License Intellectual Property for Use of MANF and CDNF to Treat Antibiotic-Induced Ototoxicity
People
Sept. 3, 2013 - Amarantus Appoints Dr. Colin Bier to Advisory Board for LymPro Commercialization
Sept. 13, 2013 - Amarantus Appoints F. Randall Grimes, MBA as Director of Sponsored Research
Nov. 6, 2013 - Amarantus Appoints David A. Lowe, PhD to Board of Directors
Feb. 24, 2014 - Amarantus Strengthens Management Team With Key Additions in Business Development and Regulatory Affairs (Kerry Segal as Head of Business Development and Tiffini Clark as Head of Regulatory Affairs)
March 31, 2014 - Amarantus Appoints Dr. Louis Kirby to Board of Advisors
April 1, 2014 - Amarantus Appoints Robert Farrell, J.D. as Chief Financial Officer
April 8, 2014 - Amarantus Appoints Dr. Charlotte Keywood Chief Medical Officer of Its Therapeutics Division
July 28, 2014 - Amarantus Appoints Donald D. Huffman to Board of Directors
Aug. 29, 2014 - Amarantus Appoints Iain Ross to Board of Directors
Place
Oct. 30, 2013 - Amarantus Relocates Headquarters to Janssen Labs @QB3 Incubator in San Francisco
May 6, 2014 - Amarantus Establishes Office in Geneva, Switzerland
Aug. 2014 - Amarantus relocates its priciple offices to larger space at 655 Montgomery Street IN San Francisco, California (5,700 sq.ft.) while continuing to lease office and laboratory space at Janssen Labs
Funding
Feb. 18, 2014 - Amarantus Bioscience Holdings Announces $3M Solicitation of Previously Issued Warrants
March 10, 2014 - Amarantus Closes Warrant Solicitation; Enters Into $20 Million Purchase Agreement With Lincoln Park Capital Fund, LLC
